|
New
Treatments
Chemotherapy
trials |
Radiation oncology
trials | Glossary of terms
The
MGH Brain Tumor Center is dedicated to the discovery
of better treatments for patients with brain tumors.
As a result, patients at the center may have the opportunity
to participate in clinical trials. To find out more
about clinical trials, review this page or call the
Center at 617.724.8770.
Chemotherapy Trials
The
Brain Tumor Center conducts studies of many new treatments.
Some of these studies are organized by the Center's
investigators working together with pharmaceutical companies,
others are performed by consortia of research hospitals
in the US and Canada. The MGH Brain Tumor Center is
a founding member of the National Cancer Institute-sponsored
cooperative clinical trials group called New Approaches to Brain Tumor Therapy (NABTT).
|
Current
Clinical Trials at the MGH Brain Tumor Center
|
|
Updated
10/17/03
|
|
Agent/Investigator |
Study Type |
Description |
Status |
Radiation
Oncology Trials
The
MGH is a participating institution in trials sponsored
by the Radiation Therapy
Oncology Group (RTOG).
|
Current
Clinical Trials at the MGH Brain Tumor Center
|
|
Agent |
Study Type |
Description |
Status |
Glossary
of Terms
Some
definitions of terms used in clinical trials of new
brain tumor treatments may be helpful.
Phase
I - A small trial, typically with only 10 to 12 patients,
designed to test the toxicity of increasing doses
of a new agent.
Phase
II - Larger trial to assess whether a agent from the
Phase I level can effectively treat a tumor.
Phase
III - Very large trial designed to compare how a new
agent from the Phase II level compares to the best
currently available agent(s).
Neoadjuvant
- Agent is administed after biospy (or surgery), but
prior to irradiation.
Adjuvant-
Agent is administered after biospy (or surgery) and
completion of irradiation.
Recurrent
- Agent is administered at the time of tumor progression
or recurrence.
|
![[Divider]](/images/barrule.gif){kind=small}
